[Yung Shin] March 2026 Revenue NT$620 Million (YoY -23.7%)

Key facts

  • [Yung Shin] March 2026 Revenue NT$620 Million (YoY -23.7%)
  • Yung Shin Pharmaceutical announced its March 2026 monthly revenue was NT$620 million, a sharp decrease of 23.7% year-over-year. This indicates challenges in the biotechnology and medical care industry.
  • Source: PR Times
  • Date: March 1, 2026

Direct answer

Yung Shin Pharmaceutical announced its March 2026 monthly revenue was NT$620 million, a sharp decrease of 23.7% year-over-year. This indicates challenges in the biotechnology and medical care industry.

Citation
[Yung Shin] March 2026 Revenue NT$620 Million (YoY -23.7%) (March 1, 2026), PR Times
Source
PR Times
Date
March 1, 2026
Yung Shin Pharmaceutical announced its March 2026 monthly revenue was NT$620 million, a sharp decrease of 23.7% year-over-year. This indicates challenges in the biotechnology and medical care industry.
生技醫療業NQ 3/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: March 1, 2026 at 09:00
  • 🔍 Collected: April 12, 2026 at 16:30 (1015h 30m after Published)
  • 🤖 AI Analyzed: April 12, 2026 at 21:21 (4h 51m after Collected)
Company Code: 3705
Company Name: Yung Shin
Industry: Biotechnology and Medical Care Industry
Data Month: 2026-03
Monthly Revenue: 620,239 thousand NTD (NT$620 million)
Year-over-Year Change: -23.7%

FAQ

What are the key facts in this article?

Yung Shin Pharmaceutical announced its March 2026 monthly revenue was NT$620 million, a sharp decrease of 23.7% year-over-year. This indicates challenges in the biotechnology and medical care industry.

What is the direct answer?

Yung Shin Pharmaceutical announced its March 2026 monthly revenue was NT$620 million, a sharp decrease of 23.7% year-over-year. This indicates challenges in the biotechnology and medical care industry.

What is the source and date?

PR Times: https://openapi.twse.com.tw/revenue/twse-rev-3705-11503 | March 1, 2026

Back to Newsroom (81)